Because changes in Tau are associated with other neurological diseases, it has also been suggested that EVs may serve as biomarkers of AD-specific tauopathy since EVs found in brain fluids of AD patients carry different pathological Tau species that distinguish them from other tauopathies, such as Pick's disease and progressive supranuclear palsy, which display morphologically different types of Tau aggregates [75]. This evidence concerns the gene MAPT and frontotemporal dementia.